HomeInsightsStock Comparison

Biocon Ltd vs Marksans Pharma Ltd Stock Comparison

Biocon Ltd vs Marksans Pharma Ltd Stock Comparison

Last Updated on: Dec 18, 2025

Key Highlights

  • The Latest Trading Price of Biocon Ltd is ₹ 356.85 as of 07 Aug 13:53.
  • The P/E Ratio of Biocon Ltd changed from 43.4 on March 2020 to 40.4 on March 2025 . This represents a CAGR of -1.19% over 6 yearsThe P/E Ratio of Marksans Pharma Ltd changed from 4.7 on March 2020 to 26.5 on March 2025 . This represents a CAGR of 33.41% over 6 years.
  • The Market Cap of Biocon Ltd changed from ₹ 32472 crore on March 2020 to ₹ 40964 crore on March 2025 . This represents a CAGR of 3.95% over 6 yearsThe Market Cap of Marksans Pharma Ltd changed from ₹ 568.95 crore on March 2020 to ₹ 10076 crore on March 2025 . This represents a CAGR of 61.45% over 6 years.
  • The revenue of Biocon Ltd for the Sep '25 is ₹ 4388 crore as compare to the Jun '25 revenue of ₹ 4021 crore. This represent the growth of 9.12% The revenue of Marksans Pharma Ltd for the Sep '25 is ₹ 741.98 crore as compare to the Jun '25 revenue of ₹ 625.63 crore. This represent the growth of 18.6%.
  • The ebitda of Biocon Ltd for the Sep '25 is ₹ 916.5 crore as compare to the Jun '25 ebitda of ₹ 828.6 crore. This represent the growth of 10.61% The ebitda of Marksans Pharma Ltd for the Sep '25 is ₹ 166.07 crore as compare to the Jun '25 ebitda of ₹ 105.76 crore. This represent the growth of 57.03%.
  • The net profit of Biocon Ltd changed from ₹ 148.9 crore to ₹ 132.8 crore over 10 quarters. This represents a CAGR of -4.47% The net profit of Marksans Pharma Ltd changed from ₹ 70.44 crore to ₹ 99.14 crore over 10 quarters. This represents a CAGR of 14.65% .
  • The Dividend Payout of Biocon Ltd changed from 69.72 % on March 2022 to 9.85 % on March 2025 . This represents a CAGR of -38.69% over 4 yearsThe Dividend Payout of Marksans Pharma Ltd changed from 10.8 % on March 2020 to 19.26 % on March 2025 . This represents a CAGR of 10.12% over 6 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Biocon Ltd

  • Biocon Limited is India's largest and fully-integrated, innovation-led biopharmaceutical company.
  • Biocon, with its key business verticals of Generics, Biosimilars, Research Services and Novel Biologics, has leveraged its affordable innovation model and scientific capabilities to develop and manufacture both small and large molecules at global scale for the benefit of patients.
  • At present, Company is engaged in the manufacture of biotechnology products and research services. Biocon Limited was incorporated in year 1978 as a joint venture between Biocon Biochemicals Limited of Ireland and an Indian entrepreneur, Kiran Mazumdar-Shaw.
  • Biocon manufactured and exported enzymes to USA and Europe during the year 1979, as first of its kind.
  • In 1989, Unilever plc acquired the Biocon Biochemicals Limited in Ireland and merges it with its subsidiary, Quest International.

About Marksans Pharma Ltd

  • Marksans Pharma Limited was formerly incorporated as Tasc Pharmaceuticals Limited in April, 1982.
  • Pursuant to the Scheme of Amalgamation, name of the Company was changed from Tasc Pharmaceuticals Limited to Marksans Pharma Limited with effect from 10th October, 2005.
  • The Company primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulation.
  • The Company's research and development facilities are located in Verna, Goa and R & D center in Navi Mumbai. In 2004-05, the Company amalgamated with M/s.
  • Marksans Pharma Limited (formerly M/s.

Biocon Ltd News Hub

News

Biocon launches GLP-1 peptide, Liraglutide in the Netherlands

Biocon announced the launch of its GLP-1 peptide, Liraglutide, for diabetes (gVictoza') an...

Read more

15 Dec 2025 09:09

News

Biocon launches its diabetes & obesity treatment drugs in Netherlands

The drug-device combination will be marketed in the Netherlands under the brand names Diav...

Read more

15 Dec 2025 09:45

News

Biocon's arm inks pact to commercialize biosimilar Aflibercept Worldwide

This follows an earlier settlement that addressed the U.S. and Canadian markets. The agree...

Read more

13 Dec 2025 15:17

News

Biocon schedules EGM

Biocon announced that an Extra Ordinary General Meeting (EGM) of the Company will be held ...

Read more

06 Dec 2025 17:54

News

Biocon Biologics to merge with Biocon

Biocon announced a strategic corporate action to fully integrate Biocon Biologics (BBL) as...

Read more

06 Dec 2025 12:36

News

Biocon to conduct board meeting

Biocon will hold a meeting of the Board of Directors of the Company on 6 December 2025. Po...

Read more

04 Dec 2025 17:16

Marksans Pharma Ltd News Hub

News

Relonchem receives UK MHRA's approval for Cetirizine Dihydrochloride 1 mg/ml Oral Solution

Marksans Pharma announced that its wholly owned subsidiary Relonchem in UK has received Ma...

Read more

20 Nov 2025 14:00

News

Marksans Pharma receives USFDA approval for Loperamide Hydrochloride tablets

Marksans Pharma announced USFDA final approval of the Company's wholly owned subsidiary Ma...

Read more

19 Nov 2025 11:32

News

Marksans Pharma's arm gets USFDA approval for Loperamide Hydrochloride 2mg tablets

The approved product is bioequivalent to the reference listed drug (RLD), Imodium A-D Tabl...

Read more

19 Nov 2025 13:30

News

Relonchem receives UK MHRA's marketing approval for two products

Marksans Pharma announced that its wholly owned subsidiary Relonchem in UK has received Ma...

Read more

17 Nov 2025 11:38

News

Marksans Pharma's Goa unit clears USFDA inspection

Marksans Pharma announced that a current Good Manufacturing Practice (cGMP) inspection was...

Read more

10 Nov 2025 14:08

News

Marksans Pharma gains after USFDA clears Goa facility with zero observations

In a filing exchange filing, the company stated that the inspection was carried out at its...

Read more

10 Nov 2025 13:03

SWOT Analysis Of Biocon Ltd

Strength

3

S

Weakness

3

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Marksans Pharma Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Biocon Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Marksans Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Biocon Ltd and Marksans Pharma Ltd

Which company has a larger market capitalization, Biocon Ltd or Marksans Pharma Ltd?

Market cap of Biocon Ltd is 51,660 Cr while Market cap of Marksans Pharma Ltd is 8,308 Cr

What are the key factors driving the stock performance of Biocon Ltd and Marksans Pharma Ltd?

The stock performance of Biocon Ltd and Marksans Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Biocon Ltd and Marksans Pharma Ltd?

As of December 18, 2025, the Biocon Ltd stock price is INR ₹386.4. On the other hand, Marksans Pharma Ltd stock price is INR ₹183.35.

How do dividend payouts of Biocon Ltd and Marksans Pharma Ltd compare?

To compare the dividend payouts of Biocon Ltd and Marksans Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions